Literature DB >> 6320825

Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.

H Y Lam.   

Abstract

The mechanism of action of tamoxifen, a triphenylethylene antiestrogen with antitumor activity, has not been fully established. In this paper, we present evidence that tamoxifen is an antagonist of calmodulin, a major cellular calcium receptor and calcium dependent regulator of many cellular processes. Our data showed that tamoxifen inhibited the activation of phosphodiesterase by calmodulin. This inhibition could be overcome by an increase in calmodulin concentration. Kinetic analysis demonstrated that tamoxifen is a competitive inhibitor of calmodulin in the activation of this enzyme. It could be speculated that the antagonism of calmodulin by tamoxifen may be one of the mechanisms responsible for its pharmacological actions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6320825     DOI: 10.1016/0006-291x(84)91062-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  53 in total

1.  Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7.

Authors:  R Grenman; K M Laine; P J Klemi; S Grenman; D J Hayashida; H Joensuu
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 2.  Regulation of insulin-like growth factors by antiestrogen.

Authors:  R Winston; P C Kao; D T Kiang
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 3.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

4.  Repurposing ospemifene for potentiating an antigen-specific immune response.

Authors:  Chiao-Jung Kao; Gregory T Wurz; Yi-Chen Lin; Daniel P Vang; Brian Phong; Michael W DeGregorio
Journal:  Menopause       Date:  2017-04       Impact factor: 2.953

5.  New piperidine derivative DTPEP acts as dual-acting anti-breast cancer agent by targeting ERα and downregulating PI3K/Akt-PKCα leading to caspase-dependent apoptosis.

Authors:  A Arun; M I Ansari; P Popli; S Jaiswal; A K Mishra; A Dwivedi; K Hajela; R Konwar
Journal:  Cell Prolif       Date:  2018-08-09       Impact factor: 6.831

6.  Estrogen receptor, calcium mobilization and rat sperm motility.

Authors:  G Sethi Saberwal; M K Sharma; N Balasinor; J Choudhary; H S Juneja
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

7.  A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro.

Authors:  F T Vertosick; R G Selker; M S Randall; M P Kristofik; T Rehn
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

9.  Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes.

Authors:  S Batra
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.

Authors:  V Wiebe; S Koester; M Lindberg; V Emshoff; J Baker; G Wurz; M DeGregorio
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.